Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity

Cancer Res (2023) 83 (19): 3252–3263.

https://doi.org/10.1158/0008-5472.CAN-23-0282

Published: 02 October 2023

View article titled, Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in <em>PIK3CA</em>- and <em>HRAS</em>-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity

Includes: Supplementary data

Journal Articles

Abstract CT047: A phase 2 study of ipatasertib in combination with pembrolizumab for first line treatment of recurrent or metastatic squamous cell cancer of the head and neck

Jacob S. Thomas, Robert Hsu, Victoria Villaflor, Jonathan Riess, Jorge Nieva, Mark Krailo, Silvio Gutkind, Dimitri Colevas

Cancer Res (2023) 83 (8_Supplement): CT047.

https://doi.org/10.1158/1538-7445.AM2023-CT047

Published: 14 April 2023

View article titled, Abstract CT047: A phase 2 study of ipatasertib in combination with pembrolizumab for first line treatment of recurrent or metastatic squamous cell cancer of the head and neck

Journal Articles

Abstract CT165: Phase II study of nivolumab and ipilimumab for treatment of metastatic/recurrent adenoid cystic carcinoma (ACC) of all anatomic sites of origin and other malignant salivary gland tumors

Young Kwang Chae, Richard Duan, Liam Il-Young Chung, Youjin Oh, Maria Matsangou, Mark Agulnik, Victoria Villaflor, Devalingam Mahalingam

Cancer Res (2023) 83 (8_Supplement): CT165.

https://doi.org/10.1158/1538-7445.AM2023-CT165

Published: 14 April 2023

View article titled, Abstract CT165: Phase II study of nivolumab and ipilimumab for treatment of metastatic/recurrent adenoid cystic carcinoma (ACC) of all anatomic sites of origin and other malignant salivary gland tumors

Journal Articles

Abstract 2688: Inhibition of CDK7 using small molecule inhibitor, TGN-1062, augments the effect of cisplatin treatment in head and neck PDX models

Trason Thode, Alexis Weston, Serina Ng, Shelby Rheinschmidt, Tithi Ghosh Halder, Sydney Adamson, Kate Gutowsky, Brian Durbin, Raffaella Soldi, Mohan Kaadige, Srinivas Kasibhatla, Haiyong Han, Justin Moser, Vincent Chung, Joseph Chao, Victoria Villaflor, Daniel D. Von Hoff, Sunil Sharma

Cancer Res (2023) 83 (7_Supplement): 2688.

https://doi.org/10.1158/1538-7445.AM2023-2688

Published: 04 April 2023

View article titled, Abstract 2688: Inhibition of CDK7 using small molecule inhibitor, TGN-1062, augments the effect of cisplatin treatment in head and neck PDX models

Journal Articles

Abstract 3931: TGN-1062 inhibits CDK7 and augments the effects of gemcitabine and nab-paclitaxel in pancreatic cancer models

Alexis Weston, Trason Thode, Ryan Rodriguez del Villar, Serina Ng, Samuel Sampson, Shelby Rheinschmidt, Tithi Ghosh Halder, Raffaella Soldi, Mohan Kaadige, Srinivas Kasibhatla, Haiyong Han, Justin Moser, Vincent Chung, Joseph Chao, Victoria Villaflor, Daniel Von Hoff, Sunil Sharma

Cancer Res (2022) 82 (12_Supplement): 3931.

https://doi.org/10.1158/1538-7445.AM2022-3931

Published: 15 June 2022

View article titled, Abstract 3931: TGN-1062 inhibits CDK7 and augments the effects of gemcitabine and nab-paclitaxel in pancreatic cancer models

Journal Articles

Abstract CT241: ENVOY-001: A phase 1, multicenter, open-label study of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in HLA-A*02+ patients with HPV16+ recurrent, locally advanced, or metastatic solid tumors

Victoria Villaflor, Rajwanth Veluswamy, Elena Garralda, Richard Maziarz, Emese Zsiros, Anthony Shields, Mariano Ponz-Sarvise, Martijn Lolkema, Mehdi Brahmi, Julia Jennings, Nathan Miselis, Lindsay Moore, Katarina Blagovic, Rui-Ru Ji, Scott Loughhead, Ricardo Zwirtes, Sandip Patel

Cancer Res (2022) 82 (12_Supplement): CT241.

https://doi.org/10.1158/1538-7445.AM2022-CT241

Published: 15 June 2022

View article titled, Abstract CT241: ENVOY-001: A phase 1, multicenter, open-label study of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in HLA-A*02+ patients with HPV16+ recurrent, locally advanced, or metastatic solid tumors

Journal Articles

Abstract 5526: Serum proteomic scores for understanding response and mechanisms of resistance to immune checkpoint inhibitors in non-small cell lung cancer

Andrew A. Davis, Jonghanne Park, Wade T. Iams, Michael S. Oh, Robert W. Lentz, Heinrich Roder, Joanna Roder, Senait Asmellash, Lelia Net, Julia Grigorieva, Nisha Mohindra, Victoria Villaflor, Young Kwang Chae

Cancer Res (2020) 80 (16_Supplement): 5526.

https://doi.org/10.1158/1538-7445.AM2020-5526

Published: 15 August 2020

View article titled, Abstract 5526: Serum proteomic scores for understanding response and mechanisms of resistance to immune checkpoint inhibitors in non-small cell lung cancer

Journal Articles

Abstract 5527: Serum proteomic scores for understanding the mechanisms of immune-related adverse events (irAEs) in non-small cell lung cancer

Andrew A. Davis, Jonghanne Park, Leeseul Kim, Gahyun Gim, Wade T. Iams, Michael S. Oh, Robert W. Lentz, Heinrich Roder, Joanna Roder, Senait Asmellash, Lelia Net, Julia Grigorieva, Nisha Mohindra, Victoria Villaflor, Young Kwang Chae

Cancer Res (2020) 80 (16_Supplement): 5527.

https://doi.org/10.1158/1538-7445.AM2020-5527

Published: 15 August 2020

View article titled, Abstract 5527: Serum proteomic scores for understanding the mechanisms of immune-related adverse events (irAEs) in non-small cell lung cancer

Journal Articles

Abstract 3644: Blood tumor mutational burden (bTMB) from circulating tumor DNA (ctDNA) as a biomarker for both mutational status and tumor burden in non-small cell lung cancer (NSCLC)

Andrew A. Davis, Carlos Galvez, Alan Pan, Nisha Mohindra, Victoria Villaflor, Young Kwang Chae

Cancer Res (2018) 78 (13_Supplement): 3644.

https://doi.org/10.1158/1538-7445.AM2018-3644

Published: 01 July 2018

View article titled, Abstract 3644: Blood tumor mutational burden (bTMB) from circulating tumor DNA (ctDNA) as a biomarker for both mutational status and tumor burden in non-small cell lung cancer (NSCLC)

Journal Articles

Abstract 658: Association of tumor mutational burden (TMB) with DNA repair mutations and response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer (NSCLC)

Andrew A. Davis, Young Kwang Chae, Sarita Agte, Alan Pan, Nisha Mohindra, Victoria Villaflor, Kirtee Raparia, Francis J. Giles

Cancer Res (2017) 77 (13_Supplement): 658.

https://doi.org/10.1158/1538-7445.AM2017-658

Published: 01 July 2017

View article titled, Abstract 658: Association of tumor mutational burden (TMB) with DNA repair mutations and response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer (NSCLC)

Journal Articles

Abstract 1861: EPHB4 as a potential therapeutic target for esophageal cancer

Rifat Hasina, Karun Mutreja, Ichiro Kawada, Rajani Kanteti, Qudsia Arif, Ren Liu, Xiuqing Li, Yue Zhou, Elizabeth Hyjek, Mark W. Lingen, Jeffery Mueller, Irving Waxman, Victoria Villaflor, Mark Ferguson, Everett E. Vokes, Parkash Gill, Ravi Salgia

Cancer Res (2012) 72 (8_Supplement): 1861.

https://doi.org/10.1158/1538-7445.AM2012-1861

Published: 15 April 2012

View article titled, Abstract 1861: EPHB4 as a potential therapeutic target for esophageal cancer

Journal Articles

Abstract 1625: Role of EphB4 in esophageal cancer: Expression, amplification, and therapeutic inhibition

Rifat Hasina, Geetanjali Kanade, Soheil Yala, Nathan Mollberg, Jeffery Muller, Mosmi Surati, Rajani Kanteti, Aliya Husain, Mitchell Posner, Irvine Waxman, Wickii Vigneswaran, Mark Ferguson, Victoria Villaflor, Everette E. Vokes, Parkash Gill, Ravi Salgia

Cancer Res (2011) 71 (8_Supplement): 1625.

https://doi.org/10.1158/1538-7445.AM2011-1625

Published: 15 April 2011

View article titled, Abstract 1625: Role of EphB4 in esophageal cancer: Expression, amplification, and therapeutic inhibition

NARROW

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity

Abstract CT047: A phase 2 study of ipatasertib in combination with pembrolizumab for first line treatment of recurrent or metastatic squamous cell cancer of the head and neck

Abstract CT165: Phase II study of nivolumab and ipilimumab for treatment of metastatic/recurrent adenoid cystic carcinoma (ACC) of all anatomic sites of origin and other malignant salivary gland tumors

Abstract 2688: Inhibition of CDK7 using small molecule inhibitor, TGN-1062, augments the effect of cisplatin treatment in head and neck PDX models

Abstract 3931: TGN-1062 inhibits CDK7 and augments the effects of gemcitabine and nab-paclitaxel in pancreatic cancer models

Abstract CT241: ENVOY-001: A phase 1, multicenter, open-label study of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in HLA-A*02+ patients with HPV16+ recurrent, locally advanced, or metastatic solid tumors

Abstract 5526: Serum proteomic scores for understanding response and mechanisms of resistance to immune checkpoint inhibitors in non-small cell lung cancer

Abstract 5527: Serum proteomic scores for understanding the mechanisms of immune-related adverse events (irAEs) in non-small cell lung cancer

Abstract 3644: Blood tumor mutational burden (bTMB) from circulating tumor DNA (ctDNA) as a biomarker for both mutational status and tumor burden in non-small cell lung cancer (NSCLC)

Abstract 658: Association of tumor mutational burden (TMB) with DNA repair mutations and response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer (NSCLC)

Abstract 1861: EPHB4 as a potential therapeutic target for esophageal cancer

Abstract 1625: Role of EphB4 in esophageal cancer: Expression, amplification, and therapeutic inhibition

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only